Influence of pretreatment with H2 receptor antagonists on the cure rates of Helicobacter pylori eradication

Medical Science Monitor

Volumn 17, Issue 5, 2011, Pages

  Tokoro, Chikako ^a   Inamori, Masahiko ^a   Koide, Tomoko ^a   Sekino, Yusuke ^a   Iida, Hiroshi ^a   Sakamoto, Yasunari ^a   Endo, Hiroki ^a   Hosono, Kunihiro ^a   Takahashi, Hirokazu ^a   Yoneda, Masato ^a   Yasuzaki, Hiroaki ^a   Ogawa, Masami ^a   Abe, Yasunobu ^a   Kubota, Kensuke ^a   Saito, Satoru ^a   Kawana, Ichiro ^a   Nakajima, Atsushi ^a   Maeda, Shin ^a   Matsuda, Reikei ^b   Takahashi, Daisuke ^c  

^a YOKOHAMA CITY UNIVERSITY HOSPITAL   (Japan)

^b Yokohama Minami Kyosai Hospital   (Japan)

^c Fujisawa Shounandai Hospital   (Japan)

Author keywords

Eradication; H2 receptor antagonist; Helicobacter pylori; Pretreatment; Proton pump inhibitor

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LAFUTIDINE; LANSOPRAZOLE; METRONIDAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

ADULT; AGED; ARTICLE; ENDOSCOPIC BIOPSY; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; UREA BREATH TEST;

EID: 79955942724     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.881762     Document Type: Article

References (43)

1. Marshall BJ, Warren JR: Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet, 1984; 1: 1311-15
2. Cover TL, Blaser MJ: Helicobacter pylori in health and disease. Gastroenterology, 2009; 136: 1863-73
3. Sato T, Chiguchi G, Inamori M et al: Protein-losing gastroenteropathy and gastric polyps: successful treatment by Helicobacter pylori eradication. Digestion, 2007; 75: 99
4. Hatakeyama M: Helicobacter pylori and gastric carcinogenesis. J Gastroenterol, 2009; 44: 239-48
5. Ferreira AC, Isomoto H, Moriyama M et al: Helicobacter and gastric malignancies. Helicobacter, 2008; 13(Suppl.1): 28-34
6. NIH Consensus Conference: Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA, 1994; 272; 65-69
7. Yilmaz Y, Gul CB, Arabul M, Eren MA: Helicobacter pylori: a role in schizophrenia? Med Sci Monit, 2008; 14(7): HY13-16
8. Konturek PC, Rienecker H, Hahn EG, Raithel M: Helicobacter pylori as a protective factor against food allergy. Med Sci Monit, 2008; 14(9): CR452-58
9. Palka M, Tomasik T, Windak A et al: The reliability of ELISA in predicting H. pylori infection in dyspeptic populations under age 45. Med Sci Monit, 2010; 16(1): PH24-28
10. Tytgat GNJ: Review article. Treatment that impact favourably upon the eradication of H. pylori and ulcer recurrence. Alim Pharmacol Ther, 1994; 8; 359-68
11. Walsh JH, Peterson WL: The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Eng J Med, 1995; 333: 984-91
12. Togawa J, Inamori M, Fujisawa N et al: Efficacy of a triple therapy with rabeprazole, amoxicillin, and faropenem as second-line treatment after failure of initial Helicobacter pylori eradication therapy. Hepatogastroenterology, 2005; 52: 645-48
13. Labenz J, Gyenes E, Rühl GH, Börsch G: Omeprazole plus amoxicillin: efficacy of various treatment regimens to eradicate Helicobacter pylori. Am J Gastroenterol, 1993; 88: 491-95
14. Labenz J, Leverkus F, Börsch G: Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Factors influencing the treatment success. Scand J Gastroenterol, 1994; 29: 1070-75
15. Bayerdörffer E, Miehlke S, Mannes GA et al: Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology, 1995; 108: 1412-17
16. Mansour-Ghanaei F, Taefeh N, Joukar F et al: Recurrence of Helicobacter pylori infection 1 year after successful eradication: a prospective study in Northern Iran. Med Sci Monit, 2010; 16(3): CR144-48
17. Malfertheiner P, Megraud F, O'Morain C et al: Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut, 2007; 56: 772-81
18. Adamek RJ, Freitag M, Opferkuch W et al: Intravenous omeprazole/ amoxicillin and omeprazole pretreatment in Helicobacter pylori-positive acute peptide ulcer bleeding. A pilot study. Scand J Gastroenterol, 1994; 29: 880-83
19. Annibale B, D'Ambra G, Luzzi I et al: Does pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients? Am J Gastroenterol, 1997; 92: 790-94
20. Adamek RJ, Szymanski C, Pfaffenbach B: Pantoprazole suppresses Helicobacter pylori without affecting cure. Helicobacter, 1999; 4: 266-71
21. Treiber G, Wittig J, Ammon S et al: Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med, 2002; 162: 153-60
22. Calabrese C, Di Febo G, Areni A et al: Pantoprazole, azithromycin and tinidazole: short duration triple therapy for eradication of Helicobacter pylori infection. Aliment Pharmacol Ther, 2000; 14: 1613-17
23. Okada M, Oki K, Shirotani T et al: A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. J Gastroenterol, 1998; 33: 640-45
24. Adachi K, Hashimoto T, Ishihara S et al: Comparison of five-day Helicobacter pylori eradication regimens: rabeprazole-based and omeprazole- based with and without omeprazole pre-treatment. Curr Ther Res Clin Exp, 2003; 64: 412-21
25. Janssen MJ, Laheij RJ, de Boer WA, Jansen JB: Meta-analysis: the influence of pre-treatment with a proton pump inhibitor on Helicobacter pylori eradication. Aliment Pharmacol Ther, 2005; 21: 341-45
26. Nakao M, Malfertheiner P: Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter, 1998; 3: 21-27
27. Goldstein NS: Chronic inactive gastritis and coccoid Helicobacter pylori in patients treated for gastroesophageal reflux disease or with H pylori eradication therapy. Am J Clin Pathol, 2002; 118: 719-26
28. Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC Jr: Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis, 1989; 8: 888-89
29. Hunt RH: pH and HP-gastric acid secretion and Helicobacter pylori: Implications for ulcer healing and eradication of the organism. Am J Gastroenterol, 1993; 88: 481-483
30. Sachs G, Shin JM, Munson K et al: Review article: the control of gastric acid and Helicobacter pylori eradication. Aliment Pharmacol Ther, 2000; 14: 1383-401
31. The European Helicobacter Pylori Study Group: Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut, 1997; 41: 8-13
32. Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W: Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin - influence on treatment outcome. Am J Gastroenterol, 1998; 93: 386-89
33. Graham DY, Hammoud F, El-Zimaity HM et al: Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther, 2003; 17: 1229-36
34. Perri F, Villani MR, Festa V, Quitadamo M, Andriulli A: Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther, 2001; 15: 1023-29
35. Janssen MJ, Laheij RJ, Jansen JB, de Boer WA: The influence of pretreatment on cure rates of Helicobacter pylori eradication. Neth J Med, 2004; 62: 192-96
36. Megraud F, Lamouliatte H: Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther, 2003; 17: 1333-43
37. Pilotto A, Leandro G, Franceschi M et al: The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. Aliment Pharmacol Ther, 1999; 13: 667-73
38. McMahon BJ, Hennessy TW, Bensler JM et al: The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med, 2003; 139: 463-69
39. Leite LP, Johnston BT, Just RJ, Castell DO: Persistant acid secretion during omeprazole therapy: a study of gastric acid profile in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol, 1996; 91: 1527-31
40. Katsube T, Adachi K, Kawamura A et al: Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Alimentary Pharmacology and Therapeutics, 2000; 14: 1049-56
41. Labenz J, Stolte M, Blum AL et al: Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut, 1995; 37: 39-43
42. Wang Y, Pan T, Wang Q, Guo Z: Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough. Cochrane Database Syst Rev, 2009; (4): CD004275
43. Maeyama S, Yoshihara H, Kamada T et al: Effect of maintenance therapy by H2RA on the recurrence of gastric and duodenal ulcer and on the occurrence of reflux esophagitis, gastric erosions, and duodenal erosions after H. pylori eradication. Nippon Rinsho, 2005; 63(Suppl.11): 512-15